Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05644054
Other study ID # TLV-16-320
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date December 2024

Study information

Verified date March 2024
Source Tel Aviv Medical Center
Contact Yara Agbaria
Phone 972522839351
Email yaraa@tlvmc.gov.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this cross-sectional, double-blind, placebo-controlled clinical trial is to enhance our understanding of the pain modulation mechanisms in females diagnosed with Fibromyalgia syndrome (FMS). This study is designed to address several key questions: 1. Is there a discernible difference in the effectiveness of the two prevalent pain modulation approaches, namely Conditioned Pain Modulation (CPM) and Offset Analgesia (OA), in individuals with FMS? To answer this, both FMS patients and an age- and sex-matched healthy control group will engage in these paradigms outside of the MRI scanner. 2. How does Tetrahydrocannabinol (THC) influence CPM and OA in FMS patients? Here, the study will observe the performance of FMS patients in both paradigms after receiving treatments with THC and a placebo, conducted outside the scanner. 3. What neural alterations in pain modulation circuits are triggered by THC? To investigate this, FMS patients will undergo the OA test inside the MRI scanner following both THC and placebo treatments. 4. How does THC affect resting-state brain function in FMS patients? This part of the study involves resting-state brain scans to measure changes in functional connectivity following treatments with THC and a placebo.


Description:

Fibromyalgia syndrome (FMS) is a condition marked by pervasive chronic pain throughout the musculoskeletal system, often accompanied by chronic sleep disturbances, fatigue, memory challenges, and more. Despite significant advancements in the understanding of pain mechanisms due to breakthroughs in neuroscience and pain medicine, current treatments for FMS fall short of providing adequate relief, leaving many patients battling ongoing pain and related symptoms. The complete pathophysiology of FMS remains elusive, but there is substantial evidence indicating the involvement of various factors, including central sensitization and impaired descending pain modulation pathways as evidenced by functional imaging studies and sensory tests such as conditioned pain modulation (CPM) and offset analgesia (OA). Given this, comprehending the pathophysiology of FMS and the mechanisms involved is crucial. Additionally, it is critical to understand how new treatments can influence pain modulation in FMS. Recent research increasingly supports the use of cannabis, particularly Tetrahydrocannabinol (THC), for alleviating chronic pain in various syndromes. Yet, there's a lack of extensive research exploring its effectiveness in randomized, double-blind trials. Exploring THC's effects in clinical pain models could enhance our understanding of pain regulation in FMS. The current study aims to deepen our understanding of sensory and neural mechanisms in FMS, employing quantitative sensory testing such as CPM and OA, and fMRI. A key objective is to ascertain the impact of THC on pain modulation in FMS within a double-blind controlled framework.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: 1. Diagnosed with fibromyalgia for over 3 months according to American college of rheumatology 2. Do not respond well to analgesic medications and or have severe side effects 3. Medium to high level of pain (over 40 on visual analogue scale scale) 4. Does not have other pain-related syndromes 5. Not treated regularly with cannabis. 6. Is ready to stop taking central nervous system medications 3 days prior to the experiment. Exclusion Criteria: 1. alleviated levels of anxiety (above 52 in STAI) 2. Psychiatric medications due to psychiatric diagnoses (depression, bi-polar syndrome, etc.). 3. Cardiovascular problems 4. Neurological diseases (other than migraine). 5. Pregnancy or breastfeeding 6. Alcoholism or substance abuse 7. Cancer 8. Blood pressure problems 9. Patients that used cannabis in the past month 10. Illegibility to MRI

Study Design


Intervention

Drug:
THC
Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)
Placebo
Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.

Locations

Country Name City State
Israel Tel Aviv Medical Center Tel Aviv

Sponsors (1)

Lead Sponsor Collaborator
Tel Aviv Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional Connectivity (FC) The variations in FC measured during the resting-state scan will be assessed using within-between network connectivity at baseline and following treatments with either THC or a placebo in FMS patients. 2 hours after drug administration
Primary Blood Oxygenation Level (BOLD) The variations in BOLD activity measured during the sensory test will be assessed using ROI to ROI analysis at baseline and following treatments with either THC or a placebo in FMS patients. 2 hours after drug administration
Primary Quantitative Sensory Tests: Conditioned pain modulation (CPM) and offset analgesia (OA) magnitude Baseline assessments of CPM and OA magnitude will be conducted for both FMS patients and their corresponding healthy control group. Furthermore, the magnitude of these tests will also be evaluated after administering either THC or placebo treatments in FMS patients. 2 hours after drug administration
See also
  Status Clinical Trial Phase
Completed NCT03149198 - Mat Pilates Method in the Treatment of Women With Fibromyalgia N/A
Completed NCT00965081 - A Study for Adult Patients With Fibromyalgia Phase 4
Enrolling by invitation NCT06100926 - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain N/A
Recruiting NCT05068791 - Psilocybin-facilitated Treatment for Chronic Pain Early Phase 1
Recruiting NCT05801497 - Balneotherapy in Primary Fibromyalgia
Active, not recruiting NCT04422522 - Fibromyalgia During the COVID-19 Pandemic
Completed NCT05361577 - Exopulse Mollii Suit and Fibromyalgia N/A
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT05941780 - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Not yet recruiting NCT06424743 - Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training N/A
Completed NCT04771260 - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting NCT04690400 - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic N/A
Enrolling by invitation NCT04098757 - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed NCT01697254 - The CARRA Registry N/A
Completed NCT00678691 - An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Phase 4
Recruiting NCT04832100 - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting NCT05688787 - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia N/A
Completed NCT03905486 - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia. N/A